[go: up one dir, main page]

MX2013014485A - Vacuna bovinas y metodos. - Google Patents

Vacuna bovinas y metodos.

Info

Publication number
MX2013014485A
MX2013014485A MX2013014485A MX2013014485A MX2013014485A MX 2013014485 A MX2013014485 A MX 2013014485A MX 2013014485 A MX2013014485 A MX 2013014485A MX 2013014485 A MX2013014485 A MX 2013014485A MX 2013014485 A MX2013014485 A MX 2013014485A
Authority
MX
Mexico
Prior art keywords
methods
bovis
hardjo
animal
infection
Prior art date
Application number
MX2013014485A
Other languages
English (en)
Other versions
MX345704B (es
Inventor
Eric Springer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013014485A publication Critical patent/MX2013014485A/es
Publication of MX345704B publication Critical patent/MX345704B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen métodos para estimular respuestas inmunes en un animal bovino susceptible a infección por Leptospira hardjo-bovis. En los métodos, se administra una composición de L. hardjo-bovis inactivado y un adyuvante al animal en aproximadamente 4 semanas desde el nacimiento. Las respuestas inmunes estimuladas en el animal previenen o acortan la duración de una posterior infección por L. hardjo-bovis. La respuesta inmune es eficaz durante al menos un año.
MX2013014485A 2011-06-10 2012-06-08 Vacuna bovinas y métodos. MX345704B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161495591P 2011-06-10 2011-06-10
PCT/US2012/041443 WO2012170753A2 (en) 2011-06-10 2012-06-08 Bovine vaccines and methods

Publications (2)

Publication Number Publication Date
MX2013014485A true MX2013014485A (es) 2014-03-21
MX345704B MX345704B (es) 2017-02-10

Family

ID=47296754

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014485A MX345704B (es) 2011-06-10 2012-06-08 Vacuna bovinas y métodos.

Country Status (6)

Country Link
US (1) US9364527B2 (es)
CA (1) CA2836805C (es)
CO (1) CO6870003A2 (es)
MX (1) MX345704B (es)
PE (1) PE20140576A1 (es)
WO (1) WO2012170753A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP6990176B2 (ja) 2015-10-05 2022-02-03 モデルナティエックス インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法
DK3407734T3 (da) 2016-01-25 2023-05-01 Signify North America Corp Biosikkerhedssystem til en landbrugsbygning

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501213A (en) * 1998-12-22 2001-09-28 Pfizer Prod Inc Isolated leptospira membrane kinase, membrane permease, membrane mannosyltransferase and endoflagellin proteins for preventing leptospirosis
WO2004017990A1 (en) * 2002-08-26 2004-03-04 Pfizer Products Inc. Vaccine for respiratory and reproductive system infections in cattle
US7563449B2 (en) * 2003-04-21 2009-07-21 Pfizer Inc, Methods for reducing cattle reproductive diseases
UY29915A1 (es) * 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
CN104758929B (zh) 2008-06-27 2018-05-25 硕腾有限责任公司 新颖的佐剂组合物

Also Published As

Publication number Publication date
PE20140576A1 (es) 2014-05-24
US20140105930A1 (en) 2014-04-17
MX345704B (es) 2017-02-10
CA2836805A1 (en) 2012-12-13
CA2836805C (en) 2023-03-07
US9364527B2 (en) 2016-06-14
CO6870003A2 (es) 2014-02-20
WO2012170753A3 (en) 2014-05-08
WO2012170753A2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
MX2013014485A (es) Vacuna bovinas y metodos.
MX2021001762A (es) Metodo y composicion para estimular la respuesta inmunitaria.
MX375202B (es) Composiciones adyuvantes novedosas.
WO2011063336A3 (en) Secondary site of antigen stimulation for therapeutic vaccination
PH12013502174B1 (en) Vaccine delivery method
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
WO2013188627A3 (en) Cationic lipid vaccine compositions and methods of use
MX373395B (es) Vacuna de haemophilus parasuis para serovar tipo cuatro.
IN2015KN00516A (es)
GB201104897D0 (en) Method for the production of protein complexes and vaccine compositions comprising the same
NZ720498A (en) Stress management in livestock
MX2015011388A (es) Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva.
RU2011108858A (ru) Средство для повышения роста и сохранности молодняка
Kang et al. Xylaria hypoxylon lectin as adjuvant elicited Tfh cell responses
WO2016018454A3 (en) Compositions and methods employing bcl2 and bcl2 family members
IN2012DN04875A (es)
UA64867U (ru) Способ лечения пиелонефритов у беременных
UA65561U (ru) Способ профилактики задержания помета у коров
UA74219U (ru) Способ стимулирования противогриппозного иммунитета
UY33780A (es) ?composiciones y métodos para vacunar ganado vacuno?.
UA91458U (uk) Спосіб корекції активності ферментів крові курчат за еймеріозної інвазії

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: NOVARTIS TIERGESUNDHEIT AG

FG Grant or registration